Rudlowski C - Search Results

1

HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.

Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, Ruehs H, Keyver-Paik MD, Rudlowski C, Weber S, Kiefer N, Poelcher ML, Thiesler T, Rostamzadeh B, Mallmann M, Schaefer N, Permantier M, Latten S, Kalff J, Thomale J, Jaehde U, Kuhn WC. Zivanovic O, et al. Among authors: rudlowski c. Int J Cancer. 2015 Feb 1;136(3):699-708. doi: 10.1002/ijc.29011. Epub 2014 Jun 17. Int J Cancer. 2015. PMID: 24895230 Clinical Trial.

2

Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.

Schneeweiss A, Huober J, Sinn HP, von Fournier D, Rudlowski C, Beldermann F, Krauss K, Solomayer E, Hamerla R, Wallwiener D, Bastert G. Schneeweiss A, et al. Among authors: rudlowski c. Eur J Cancer. 2004 Nov;40(16):2432-8. doi: 10.1016/j.ejca.2004.08.004. Eur J Cancer. 2004. PMID: 15519516 Clinical Trial.

3

Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.

Schneeweiss A, Schuetz F, Rudlowski C, Hahn M, Lauschner I, Sinn HP, von Fournier D, Sohn C. Schneeweiss A, et al. Among authors: rudlowski c. Anticancer Drugs. 2005 Oct;16(9):1023-8. doi: 10.1097/01.cad.0000176508.73090.fb. Anticancer Drugs. 2005. PMID: 16162980 Clinical Trial.

4

Comparative genomic hybridization analysis on male breast cancer.

Rudlowski C, Schulten HJ, Golas MM, Sander B, Barwing R, Palandt JE, Schlehe B, Lindenfelser R, Moll R, Liersch T, Schumpelick V, Gunawan B, Füzesi L. Rudlowski C, et al. Int J Cancer. 2006 May 15;118(10):2455-60. doi: 10.1002/ijc.21646. Int J Cancer. 2006. PMID: 16353155

5

Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.

Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S, Schroeder W. Rudlowski C, et al. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:183-9. doi: 10.1111/j.1525-1438.2006.00307.x. Int J Gynecol Cancer. 2006. PMID: 16515588

6

Influence of preoperative MRI on the surgical management of patients with operable breast cancer.

Braun M, Pölcher M, Schrading S, Zivanovic O, Kowalski T, Flucke U, Leutner C, Park-Simon TW, Rudlowski C, Kuhn W, Kuhl CK. Braun M, et al. Among authors: rudlowski c. Breast Cancer Res Treat. 2008 Sep;111(1):179-87. doi: 10.1007/s10549-007-9767-5. Epub 2007 Sep 29. Breast Cancer Res Treat. 2008. PMID: 17906928

7

Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).

Pölcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Höss C, Leutner C, Braun M, Möbus V, Karbe I, Stimmler P, Rudlowski C, Schwarz J, Kuhn W. Pölcher M, et al. Among authors: rudlowski c. Oncol Rep. 2009 Sep;22(3):605-13. doi: 10.3892/or_00000479. Oncol Rep. 2009. PMID: 19639211 Clinical Trial.

8

Detection of lymphovascular invasion in vulvar cancer by D2-40 (podoplanin) as a predictor for inguinal lymph node metastases.

Braun M, Wardelmann E, Debald M, Walgenbach-Bruenagel G, Höller T, Wolfgarten M, Sauerwald A, Rudlowski C, Büttner R, Kuhn W, Pölcher M. Braun M, et al. Among authors: rudlowski c. Onkologie. 2009 Dec;32(12):732-8. doi: 10.1159/000252795. Epub 2009 Nov 20. Onkologie. 2009. PMID: 20016234

9

Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapy.

Classen S, Muth C, Debey-Pascher S, Eggle D, Beyer M, Mallmann MR, Rudlowski C, Zander T, Pölcher M, Kuhn W, Lahn M, Schultze JL, Staratschek-Jox A. Classen S, et al. Among authors: rudlowski c. Pharmacogenet Genomics. 2010 Mar;20(3):147-56. doi: 10.1097/FPC.0b013e328335731c. Pharmacogenet Genomics. 2010. PMID: 20084050

10

Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.

Pölcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kübler K, Büttner R, Kuhn WC, Hernando JJ. Pölcher M, et al. Among authors: rudlowski c. Cancer Immunol Immunother. 2010 Jun;59(6):909-19. doi: 10.1007/s00262-010-0817-1. Epub 2010 Jan 20. Cancer Immunol Immunother. 2010. PMID: 20087581 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters